Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL

International Braz J Urol

Volumn 34, Issue 3, 2008, Pages 283-290

  Leite, Katia R M ^a,b,c   Srougi, Miguel ^a   Dall'Oglio, Marcos F ^a   Sanudo, Adriana ^a   Camara Lopes, Luiz H ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Laboratory of Surgical and Molecular Pathology   (Brazil)

^c NONE   (Brazil)

Author keywords

Biopsy; Diagnosis; Gleason score; Prostate cancer; PSA; Tumor volume

Indexed keywords

EID: 48049090693     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/s1677-55382008000300005     Document Type: Article

References (32)

1. Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H: Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998; 73: 401-6.
2. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Tomaszewski JE, et al.: The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol. 1998; 160: 2096-101.
3. Stephenson RA: Population-based prostate cancer trends in the PSA era data from the Surveillance, Epidemiology, and End Results (SEER) Program. Monogr Urol. 1998; 19: 3-19.
4. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK: Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997; 158: 1427-30.
5. Catalona WJ, Loeb S: The PSA era is not over for prostate cancer. Eur Urol. 2005; 48: 541-5.
6. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC: Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001; 166: 416-9.
7. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324: 1156-61. Erratum in: N Engl J Med 1991; 325: 1324.
8. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993; 270: 948-54.
9. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y: Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000; 55: 791-5.
10. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, et al.: Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology. 2002; 60: 469-73; discussion 473-4.
11. Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R: Prostate cancer detection at low prostate specific antigen. J Urol. 2000; 163: 806-12.
12. Zhu H, Roehl KA, Antenor JA, Catalona WJ: Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology. 2005; 66: 547-51.
13. Siu W, Dunn RL, Shah RB, Wei JT: Use of extended pattern technique for initial prostate biopsy. J Urol. 2005; 174: 505-9.
14. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, et al.: Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005; 216: 34-63.
15. Humphrey PA, Vollmer RT: Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum Pathol. 1990; 21: 799-804.
16. Greene FL, Page DL, Fleming ID: AJCC Cancer Staging Manual. 6th edition. New York, Springer; 2002.
17. Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271: 368-74.
18. Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, et al.: Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int. 2007; 99: 753-7.
19. Dall'Oglio MF, Crippa A, Passerotti CC, Nesrallah LJ, Leite KR, Srougi M: Serum PSA and cure perspective for prostate cancer in males with nonpalpable tumor. Int Braz J Urol. 2005; 31: 437-44.
20. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y: Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000; 55: 791-5.
21. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-46. Erratum in: N Engl J Med. 2004; 351: 1470.
22. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB: Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006; 67: 316-20.
23. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005; 352: 1977-84.
24. Rubin MA, Bassily N, Sanda M, Montie J, Strawderman MS, Wojno K: Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. Am J Surg Pathol. 2000; 24: 183-9.
25. Freedland SJ, Csathy GS, Dorey F, Aronson WJ: Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy. Urology. 2002; 60: 84-8.
26. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM: Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999; 281: 1395-400.
27. McNeal JE: Prostate cancer volume. Am J Surg Pathol. 1997; 21: 1392-3.
28. Fang J, Metter EJ, Landis P, Carter HB: PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology. 2002; 59: 889-93; discussion 893-4.
29. Berger AP, Diebl M, Steiner H, Bektic J, Pelzer A, Leonhartsberger N et al., Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. J Urol. 2005; 173 (Suppl. 4): 402.
30. Catalona WJ, Loeb S: The PSA era is not over for prostate cancer. Eur Urol. 2005; 48: 541-5.
31. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, et al.: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006; 98: 1521-7.
32. Yu X, Loeb S, Roehl KA, Han M, Catalona WJ: The association between total prostate specific antigen concentration and prostate specific antigen velocity. J Urol. 2007; 177: 1298-302; discussion 1301-2.